Literature DB >> 30816329

BCL2 blockade overcomes MCL1 resistance in multiple myeloma.

Ka Tat Siu1, Cherrie Huang2, Cristina Panaroni1, Kenta Mukaihara1, Keertik Fulzele1, Rosemary Soucy1, Cassandra Thorburn1, Justin Cidado3, Lisa Drew3, Shrikanta Chattopadhyay2, Noopur Raje4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30816329     DOI： 10.1038/s41375-019-0421-0

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.

Authors:  Anne Slomp; Laura M Moesbergen; Jia-Nan Gong; Marta Cuenca; Peter A von dem Borne; Pieter Sonneveld; David C S Huang; Monique C Minnema; Victor Peperzak
Journal:  Blood Adv       Date:  2019-12-23

2.  Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.

Authors:  Kallesh D Jayappa; Vicki L Gordon; Christopher G Morris; Briana Wilson; B Dharmaveer Shetty; Konrad J Cios; Puja C Arora; Krista M Isaac; Shekhar Saha; Timothy P Bender; Michael E Williams; Craig A Portell; Michael J Weber
Journal:  Blood Adv       Date:  2021-09-14

3.  ZNF143 Suppresses Cell Apoptosis and Promotes Proliferation in Gastric Cancer via ROS/p53 Axis.

Authors:  Yi Zhang; Qing Li; Song Wei; Jing Sun; Xuan Zhang; Ling He; Lu Zhang; Zekuan Xu; Dexuan Chen
Journal:  Dis Markers       Date:  2020-01-28       Impact factor: 3.434

Review 4.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

5.  Skp2 stabilizes Mcl-1 and confers radioresistance in colorectal cancer.

Authors:  Xinfang Yu; Li Zhou; Wenbin Liu; Lijun Liu; Feng Gao; Wei Li; Haidan Liu
Journal:  Cell Death Dis       Date:  2022-03-18       Impact factor: 9.685

6.  Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia.

Authors:  Sabrina Kraus; Martin K Kortüm; Andoni Garitano-Trojaola; Ana Sancho; Ralph Götz; Patrick Eiring; Susanne Walz; Hardikkumar Jetani; Jesus Gil-Pulido; Matteo Claudio Da Via; Eva Teufel; Nadine Rhodes; Larissa Haertle; Estibaliz Arellano-Viera; Raoul Tibes; Andreas Rosenwald; Leo Rasche; Michael Hudecek; Markus Sauer; Jürgen Groll; Hermann Einsele
Journal:  Commun Biol       Date:  2021-06-25

7.  Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.

Authors:  Carolane Seiller; Sophie Maiga; Cyrille Touzeau; Céline Bellanger; Charlotte Kervoëlen; Géraldine Descamps; Laurent Maillet; Philippe Moreau; Catherine Pellat-Deceunynck; Patricia Gomez-Bougie; Martine Amiot
Journal:  Cell Death Dis       Date:  2020-05-05       Impact factor: 8.469

8.  Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.

Authors:  Feng Gao; Xinfang Yu; Ming Li; Li Zhou; Wenbin Liu; Wei Li; Haidan Liu
Journal:  Cell Death Dis       Date:  2020-02-21       Impact factor: 8.469

9.  mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation.

Authors:  Naoki Osada; Jiro Kikuchi; Daisuke Koyama; Yoshiaki Kuroda; Hiroshi Yasui; Joel D Leverson; Yusuke Furukawa
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941

10.  Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.

Authors:  Arnold Bolomsky; Juho J Miettinen; Alina Malyutina; Andrej Besse; Julia Huber; Stefanie Fellinger; Helene Breid; Alun Parsons; Kristaps Klavins; J Thomas Hannich; Stefan Kubicek; Jo Caers; Wolfgang Hübl; Martin Schreder; Niklas Zojer; Christoph Driessen; Jing Tang; Lenka Besse; Caroline A Heckman; Heinz Ludwig
Journal:  Blood Adv       Date:  2021-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.